Acepromazine
Magnesium hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aceprometazine
Magnesium hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alclometasone
The bioavailability of Alclometasone can be decreased when combined with Magnesium hydroxide.
Advertisement
Aldosterone
The bioavailability of Aldosterone can be decreased when combined with Magnesium hydroxide.
Alendronate
The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.
Alendronic acid
The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.
Advertisement
Alfacalcidol
The serum concentration of Magnesium hydroxide can be increased when it is combined with Alfacalcidol.
Allopurinol
Magnesium hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amcinonide
The bioavailability of Amcinonide can be decreased when combined with Magnesium hydroxide.
Advertisement
Amiodarone
The risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium hydroxide.
Amlodipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium hydroxide.
Amphetamine
Magnesium hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Androstenedione
The bioavailability of Androstenedione can be decreased when combined with Magnesium hydroxide.
Atazanavir
Magnesium hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atorvastatin
The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium hydroxide.
Atracurium
Magnesium hydroxide may increase the neuromuscular blocking activities of Atracurium.
Atracurium Besylate
Magnesium hydroxide may increase the neuromuscular blocking activities of Atracurium besylate.
Beclomethasone Dipropionate
The bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium hydroxide.
Bencyclane
The risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium hydroxide.
Benzphetamine
Magnesium hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.
Bepridil
The risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium hydroxide.
Betamethasone
The bioavailability of Betamethasone can be decreased when combined with Magnesium hydroxide.
Bioallethrin
The risk or severity of hypotension and neuromuscular blockade can be increased when Bioallethrin is combined with Magnesium hydroxide.
Bisacodyl
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium hydroxide.
Bismuth Subcitrate
The therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium hydroxide.
Bosutinib
The serum concentration of Bosutinib can be decreased when it is combined with Magnesium hydroxide.
Bosutinib monohydrate
The serum concentration of Bosutinib can be decreased when it is combined with Magnesium hydroxide.
Budesonide
The bioavailability of Budesonide can be decreased when combined with Magnesium hydroxide.
Calcitriol
The serum concentration of Magnesium hydroxide can be increased when it is combined with Calcitriol.
Captopril
Magnesium hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefditoren
The serum concentration of Cefditoren can be decreased when it is combined with Magnesium hydroxide.
Cefpodoxime
The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium hydroxide.
Cefuroxime
The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium hydroxide.
Cerivastatin
The serum concentration of Cerivastatin can be decreased when it is combined with Magnesium hydroxide.
Chloroquine
The serum concentration of Chloroquine can be decreased when it is combined with Magnesium hydroxide.
Chlorpromazine
Magnesium hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlortetracycline
Magnesium hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciclesonide
The bioavailability of Ciclesonide can be decreased when combined with Magnesium hydroxide.
Cinnarizine
The risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium hydroxide.
Cinoxacin
Magnesium hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin
Magnesium hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cisatracurium
Magnesium hydroxide may increase the neuromuscular blocking activities of Cisatracurium.
Clevidipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium hydroxide.
Clevidipine butyrate
The risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium hydroxide.
Clobetasol
The bioavailability of Clobetasol can be decreased when combined with Magnesium hydroxide.
Clobetasol Propionate
The bioavailability of Clobetasol propionate can be decreased when combined with Magnesium hydroxide.
Clobetasone
The bioavailability of Clobetasone can be decreased when combined with Magnesium hydroxide.
Clocortolone
The bioavailability of Clocortolone can be decreased when combined with Magnesium hydroxide.
Clodronic Acid
The serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium hydroxide.
Cortisone Acetate
The bioavailability of Cortisone acetate can be decreased when combined with Magnesium hydroxide.
Cyclandelate
The risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium hydroxide.
Cysteamine
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium hydroxide.
Dabigatran Etexilate
The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium hydroxide.
Dabrafenib
The serum concentration of Dabrafenib can be decreased when it is combined with Magnesium hydroxide.
Dasatinib
Magnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Anhydrous
Magnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferiprone
The serum concentration of Deferiprone can be decreased when it is combined with Magnesium hydroxide.
Deflazacort
The bioavailability of Deflazacort can be decreased when combined with Magnesium hydroxide.
Delavirdine
The serum concentration of Delavirdine can be decreased when it is combined with Magnesium hydroxide.
Demeclocycline
Magnesium hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Desonide
The bioavailability of Desonide can be decreased when combined with Magnesium hydroxide.
Desoximetasone
The bioavailability of Desoximetasone can be decreased when combined with Magnesium hydroxide.
Desoxycorticosterone acetate
The bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium hydroxide.
Desoxycorticosterone Pivalate
The bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium hydroxide.
Dexamethasone
The bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.
Dexmethylphenidate
Magnesium hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dextroamphetamine
Magnesium hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.
Dibasic potassium phosphate
Magnesium hydroxide can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Diethylpropion
Magnesium hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.
Diflorasone
The bioavailability of Diflorasone can be decreased when combined with Magnesium hydroxide.
Diflucortolone
The bioavailability of Difluocortolone can be decreased when combined with Magnesium hydroxide.
Difluprednate
The bioavailability of Difluprednate can be decreased when combined with Magnesium hydroxide.
Diltiazem
The risk or severity of hypotension and neuromuscular blockade can be increased when Diltiazem is combined with Magnesium hydroxide.
Dolutegravir
The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium hydroxide.
Doxacurium Chloride
Magnesium hydroxide may increase the neuromuscular blocking activities of Doxacurium chloride.
Doxycycline
Magnesium hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Doxycycline Anhydrous
Magnesium hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eltrombopag
The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium hydroxide.
Elvitegravir
The serum concentration of Elvitegravir can be decreased when it is combined with Magnesium hydroxide.
Enoxacin
Magnesium hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib
The serum concentration of Erlotinib can be decreased when it is combined with Magnesium hydroxide.
Estrone
The bioavailability of Estrone can be decreased when combined with Magnesium hydroxide.
Ethosuximide
The risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium hydroxide.
Etidronate
The serum concentration of Etidronic acid can be decreased when it is combined with Magnesium hydroxide.
Etidronic Acid
The serum concentration of Etidronic acid can be decreased when it is combined with Magnesium hydroxide.
Felodipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.
Fendiline
The risk or severity of hypotension and neuromuscular blockade can be increased when Fendiline is combined with Magnesium hydroxide.
Ferric Carboxymaltose
Magnesium hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric Pyrophosphate
Magnesium hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fexofenadine
The serum concentration of Fexofenadine can be decreased when it is combined with Magnesium hydroxide.
Fish Oils
The risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium hydroxide.
Fleroxacin
Magnesium hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fludrocortisone
The bioavailability of Fludrocortisone can be decreased when combined with Magnesium hydroxide.
Flumequine
Magnesium hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumethasone
The bioavailability of Flumethasone can be decreased when combined with Magnesium hydroxide.
Flunarizine
The risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium hydroxide.
Flunisolide
The bioavailability of Flunisolide can be decreased when combined with Magnesium hydroxide.
Flunisolide Anhydrous (obsolete)
The bioavailability of Flunisolide can be decreased when combined with Magnesium hydroxide.
Fluocinolone Acetonide
The bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium hydroxide.
Fluocinonide
The bioavailability of Fluocinonide can be decreased when combined with Magnesium hydroxide.
Fluocortolone
The bioavailability of Fluocortolone can be decreased when combined with Magnesium hydroxide.
Fluorometholone
The bioavailability of Fluorometholone can be decreased when combined with Magnesium hydroxide.
Fluphenazine
Magnesium hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FLUPREDNIDENE
The bioavailability of Fluprednidene can be decreased when combined with Magnesium hydroxide.
Fluprednisolone
The bioavailability of Fluprednisolone can be decreased when combined with Magnesium hydroxide.
Flurandrenolide
The bioavailability of Flurandrenolide can be decreased when combined with Magnesium hydroxide.
Fluspirilene
The risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium hydroxide.
Fluticasone
The bioavailability of Fluticasone can be decreased when combined with Magnesium hydroxide.
Fluticasone Furoate
The bioavailability of Fluticasone furoate can be decreased when combined with Magnesium hydroxide.
Fluticasone propionate
The bioavailability of Fluticasone propionate can be decreased when combined with Magnesium hydroxide.
Fluvastatin
The serum concentration of Fluvastatin can be decreased when it is combined with Magnesium hydroxide.
Formestane
The bioavailability of Formestane can be decreased when combined with Magnesium hydroxide.
Fosinopril
Magnesium hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gabapentin
The serum concentration of Gabapentin can be decreased when it is combined with Magnesium hydroxide.
Gallamine Triethiodide
Magnesium hydroxide may increase the neuromuscular blocking activities of Gallamine Triethiodide.
Gallopamil
The risk or severity of hypotension and neuromuscular blockade can be increased when Gallopamil is combined with Magnesium hydroxide.
Gatifloxacin
Magnesium hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin Anhydrous
Magnesium hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gefitinib
The serum concentration of Gefitinib can be decreased when it is combined with Magnesium hydroxide.
Gemifloxacin
Magnesium hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin Mesylate
Magnesium hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin
Magnesium hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Halcinonide
The bioavailability of Halcinonide can be decreased when combined with Magnesium hydroxide.
Halobetasol
The bioavailability of Ulobetasol can be decreased when combined with Magnesium hydroxide.
Hydrocortisone
The bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.
Hyoscyamine
The serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium hydroxide.
Ibandronate
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.
Ibandronic Acid
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.
Inamrinone
The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium hydroxide.
Iron
Magnesium hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Carbonyl
Magnesium hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Sucrose
Magnesium hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron-Dextran Complex
Magnesium hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isoniazid
Magnesium hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isradipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Isradipine is combined with Magnesium hydroxide.
Itraconazole
The serum concentration of Itraconazole can be decreased when it is combined with Magnesium hydroxide.
Ketoconazole
The serum concentration of Ketoconazole can be decreased when it is combined with Magnesium hydroxide.
Lacidipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium hydroxide.
Lamotrigine
The risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium hydroxide.
Ledipasvir
The serum concentration of Ledipasvir can be decreased when it is combined with Magnesium hydroxide.
Lercanidipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium hydroxide.
Levetiracetam
The risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium hydroxide.
Levofloxacin
Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin Anhydrous
Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
LEVOMENTHOL
The risk or severity of hypotension and neuromuscular blockade can be increased when Menthol is combined with Magnesium hydroxide.
Levothyroxine
The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium hydroxide.
Lisdexamfetamine
Magnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.
Lisdexamfetamine Dimesylate
Magnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.
Lomefloxacin
Magnesium hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Loperamide
The risk or severity of hypotension and neuromuscular blockade can be increased when Loperamide is combined with Magnesium hydroxide.
Loteprednol
The bioavailability of Loteprednol can be decreased when combined with Magnesium hydroxide.
Lovastatin
The serum concentration of Lovastatin can be decreased when it is combined with Magnesium hydroxide.
Magnesium Sulfate
The risk or severity of hypotension and neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium hydroxide.
MAGNESIUM SULFATE ANHYDROUS
The risk or severity of hypotension and neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium hydroxide.
Manidipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Manidipine is combined with Magnesium hydroxide.
Mecamylamine
The serum concentration of Mecamylamine can be increased when it is combined with Magnesium hydroxide.
Medronate
The serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium hydroxide.
Medrysone
The bioavailability of Medrysone can be decreased when combined with Magnesium hydroxide.
Memantine
The serum concentration of Memantine can be increased when it is combined with Magnesium hydroxide.
Menthol
The risk or severity of hypotension and neuromuscular blockade can be increased when Menthol is combined with Magnesium hydroxide.
Mephentermine
Magnesium hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.
Mepirodipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium hydroxide.
Mesalamine
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium hydroxide.
Mesoridazine
Magnesium hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methamphetamine
Magnesium hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.
Methenamine
The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium hydroxide.
Methotrimeprazine
Magnesium hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methsuximide
The risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium hydroxide.
Methylene blue
Magnesium hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate
Magnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methylprednisolone
The bioavailability of Methylprednisolone can be decreased when combined with Magnesium hydroxide.
Metocurine
Magnesium hydroxide may increase the neuromuscular blocking activities of Metocurine.
Metocurine iodide
Magnesium hydroxide may increase the neuromuscular blocking activities of Metocurine Iodide.
Mibefradil
The risk or severity of hypotension and neuromuscular blockade can be increased when Mibefradil is combined with Magnesium hydroxide.
Minocycline
Magnesium hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Misoprostol
The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Misoprostol.
Mivacurium
Magnesium hydroxide may increase the neuromuscular blocking activities of Mivacurium.
Mometasone
The bioavailability of Mometasone can be decreased when combined with Magnesium hydroxide.
Moricizine
Magnesium hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Moxifloxacin
Magnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
MYCOPHENOLATE
Magnesium hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic Acid
Magnesium hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic Acid
Magnesium hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nicardipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nicardipine is combined with Magnesium hydroxide.
Nifedipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium hydroxide.
Nilotinib
The serum concentration of Nilotinib can be decreased when it is combined with Magnesium hydroxide.
Nilvadipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nilvadipine is combined with Magnesium hydroxide.
Nimesulide
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimesulide is combined with Magnesium hydroxide.
Nimodipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium hydroxide.
Nisoldipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium hydroxide.
Nitrendipine
The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide.
Norfloxacin
Magnesium hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nylidrin
The risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium hydroxide.
Octylonium
The risk or severity of hypotension and neuromuscular blockade can be increased when Otilonium is combined with Magnesium hydroxide.
Ofloxacin
Magnesium hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline
Magnesium hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline Anhydrous
Magnesium hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
p-Hydroxyamphetamine
Magnesium hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.
Pamidronate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium hydroxide.
Pamidronic Acid
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium hydroxide.
Pancuronium
Magnesium hydroxide may increase the neuromuscular blocking activities of Pancuronium.
Pancuronium Bromide
Magnesium hydroxide may increase the neuromuscular blocking activities of Pancuronium.
Paramethasone
The bioavailability of Paramethasone can be decreased when combined with Magnesium hydroxide.
Pazopanib
The serum concentration of Pazopanib can be decreased when it is combined with Magnesium hydroxide.
Pefloxacin
Magnesium hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penicillamine
The serum concentration of Penicillamine can be decreased when it is combined with Magnesium hydroxide.
Perazine
Magnesium hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Periciazine
Magnesium hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perphenazine
Magnesium hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phentermine
Magnesium hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.
PHENTERMINE RESIN
Magnesium hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.
Pinaverium
The risk or severity of hypotension and neuromuscular blockade can be increased when Pinaverium is combined with Magnesium hydroxide.
Pipecuronium
Magnesium hydroxide may increase the neuromuscular blocking activities of Pipecuronium.
Pitavastatin
The serum concentration of Pitavastatin can be decreased when it is combined with Magnesium hydroxide.
Polystyrene Sulfonate
The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Tolevamer.
Polystyrene Sulfonic Acid
The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Tolevamer.
Prasterone
The bioavailability of Prasterone can be decreased when combined with Magnesium hydroxide.
Pravastatin
The serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide.
Prednicarbate
The bioavailability of Prednicarbate can be decreased when combined with Magnesium hydroxide.
Prednisolone
The bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.
Prednisone
The bioavailability of Prednisone can be decreased when combined with Magnesium hydroxide.
Pregnenolone
The bioavailability of Pregnenolone can be decreased when combined with Magnesium hydroxide.
Prenylamine
The risk or severity of hypotension and neuromuscular blockade can be increased when Prenylamine is combined with Magnesium hydroxide.
Prochlorperazine
Magnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promazine
Magnesium hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promethazine
Magnesium hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pseudoephedrine
Magnesium hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.
Pyrantel
Magnesium hydroxide may increase the neuromuscular blocking activities of Pyrantel.
Quinidine
Magnesium hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.
Quinine
The serum concentration of Quinine can be decreased when it is combined with Magnesium hydroxide.
Raltegravir
The serum concentration of Raltegravir can be decreased when it is combined with Magnesium hydroxide.
Rapacuronium
Magnesium hydroxide may increase the neuromuscular blocking activities of Rapacuronium.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Magnesium hydroxide.
Rimexolone
The bioavailability of Rimexolone can be decreased when combined with Magnesium hydroxide.
Riociguat
The serum concentration of Riociguat can be decreased when it is combined with Magnesium hydroxide.
Risedronate
The serum concentration of Risedronate can be decreased when it is combined with Magnesium hydroxide.
Risedronic Acid
The serum concentration of Risedronate can be decreased when it is combined with Magnesium hydroxide.
Rocuronium
Magnesium hydroxide may increase the neuromuscular blocking activities of Rocuronium.
Rosoxacin
Magnesium hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosuvastatin
The serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium hydroxide.
Simvastatin
The serum concentration of Simvastatin can be decreased when it is combined with Magnesium hydroxide.
Sodium glycerophosphate
Magnesium hydroxide can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
SODIUM GLYCEROPHOSPHATE ANHYDROUS
Magnesium hydroxide can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium Phosphate
Magnesium hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium Phosphate, Monobasic
Magnesium hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Magnesium hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sotalol
The serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.
Sparfloxacin
Magnesium hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Succinylcholine
Magnesium hydroxide may increase the neuromuscular blocking activities of Succinylcholine.
Sucroferric Oxyhydroxide
Magnesium hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sulpiride
The serum concentration of Sulpiride can be decreased when it is combined with Magnesium hydroxide.
Technetium Tc 99m Medronate
The serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium hydroxide.
Temafloxacin
Magnesium hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetracycline
Magnesium hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thiethylperazine
Magnesium hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioctic Acid
Magnesium hydroxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioproperazine
Magnesium hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioridazine
Magnesium hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tiludronate
The serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium hydroxide.
Tiludronic Acid
The serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium hydroxide.
Tixocortol
The bioavailability of Tixocortol can be decreased when combined with Magnesium hydroxide.
Tolfenamic Acid
The risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium hydroxide.
Tranilast
The risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium hydroxide.
Triamcinolone
The bioavailability of Triamcinolone can be decreased when combined with Magnesium hydroxide.
Trientine
Magnesium hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trifluoperazine
Magnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triflupromazine
Magnesium hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trimebutine
The risk or severity of hypotension and neuromuscular blockade can be increased when Trimebutine is combined with Magnesium hydroxide.
Trimeprazine
Magnesium hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trimethadione
The risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium hydroxide.
Trovafloxacin
Magnesium hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tubocurarine
Magnesium hydroxide may increase the neuromuscular blocking activities of Tubocurarine.
Vecuronium
Magnesium hydroxide may increase the neuromuscular blocking activities of Vecuronium.
Verapamil
The risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium hydroxide.
Vinpocetine
The risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium hydroxide.
Ziconotide
The risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium hydroxide.
Zoledronic Acid
The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium hydroxide.
Zoledronic Acid Anhydrous
The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium hydroxide.
Zonisamide
The risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium hydroxide.
